Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Xu, Lei ^a   Zang, Panpan ^b   Feng, Bo ^a   Qian, Qiaohui ^c  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c Department of Nephrology Shanghai ZhouPu Hospital   (China)

Author keywords

AGEs; Atherosclerosis; Atorvastatin; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; BOVINE SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA WALL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ATHEROSCLEROSIS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PLEIOTROPY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; UPREGULATION; WESTERN BLOTTING;

EID: 84907911010     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-102     Document Type: Article

References (36)

1. Glucose and diabetic vascular disease. Ruderman NB, Williamson JR, Brownlee M, FABEB J 1992 6 2905 2914
2. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Yan SF, Ramasamy R, Naka Y, Schmidt AM, Circ Res 2003 93 1159 1169 10.1161/01.RES.0000103862.26506.3D 14670831
3. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Migheli A, Stern D, Am J Pathol 1993 143 1699 1712 8256857
4. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, De Cuccurullo C, Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Circulation 2003 108 1070 1077 10.1161/01.CIR.0000086014.80477.0D 12912808
5. Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. Huttunen HJ, Fages C, Rauvala H, J Biol Chem 1999 274 19919 19924 10.1074/jbc.274.28.19919 10391939
6. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP, Diabetes 2001 50 2792 2808 10.2337/diabetes.50.12.2792 11723063
7. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. Shanmugam N, Kim YS, Lanting L, Natarajan R, J Biol Chem 2003 278 34834 34844 10.1074/jbc.M302828200 12837757
8. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM, Nat Med 1998 4 1025 1031 10.1038/2012 9734395
9. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group, Lancet 2003 361 2005 2016 12814710
10. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators, Lancet 2003 361 1149 1158 10.1016/S0140-6736(03)12948-0 12686036
11. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, LIPID Study Group, Diabetes Care 2003 26 2713 2721 10.2337/diacare.26.10.2713 14514569
12. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators, Lancet 2004 364 685 696 10.1016/S0140-6736(04)16895-5 15325833
13. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Laufs U, La Fata V, Plutzky J, Liao JK, Circulation 1998 97 1129 1135 10.1161/01.CIR.97.12.1129 9537338
14. Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin. Li M, Liu Y, Dutt P, Fanburg BL, Toksoz D, Am J Physiol Lung Cell Mol Physiol 2007 293 463 L471 10.1152/ajplung.00133.2007 17545489
15. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Scalia R, Gooszen ME, Jones SP, Hoffmeyer M, Rimmer DM 3rd, Trocha SD, Huang PL, Smith MB, Lefer AM, Lefer DJ, Circulation 2001 103 2598 2603 10.1161/01.CIR.103.21.2598 11382730
16. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Feng B, Xu L, Wang H, Yan X, Xue J, Liu F, Hu JF, Biochim Biophys Acta 2011 1812 1130 1137 10.1016/j.bbadis.2011.05.007 21651980
17. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Bernini F, Poli A, Paoletti R, Cardiovasc Drugs Ther 2001 15 211 218 10.1023/A:1011908004965 11713888
18. Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin. Dostal LA, Whitfield LR, Anderson JA, Fundam Appl Toxicol 1996 32 285 292 10.1006/faat.1996.0132 8921332
19. Beneficial cardiovascular pleiotropic effects of statins. Davignon J, Circulation 2004 109 23 Suppl 1 II39 III43 15198965
20. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. Ray KK, Cannon CP, J Am Coll Cardiol 2005 46 1425 1433 10.1016/j.jacc.2005.05.086 16226165
21. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. Okamoto T, Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z, FASEB J 2002 16 1928 1930 12368225
22. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation,oxidative stress and inflammation. Calkin AC, Giunti C, Sheehy KJ, Chew C, Boolell V, Rajaram YS, Cooper ME, Jandeleit-Dahm KA, Diabetologia 2008 51 1731 1740 10.1007/s00125-008-1060-6 18594792
23. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Cuccurullo C, Iezzi A, Fazia ML, De Cesare D, Di Francesco A, Muraro R, Bei R, Ucchino S, Spigonardo F, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A, Cipollone F, Arterioscler Thromb Vasc Biol 2006 26 2716 2723 10.1161/01.ATV.0000249630.02085.12 17038636
24. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic Men. A population-based 18-year follow-up study. Kilhovd BK, Juutilainen A, Lehto S, Rönnemaa T, Torjesen PA, Birkeland KI, Berg TJ, Hanssen KF, Laakso M, Arterioscler Thromb Vasc Biol 2005 25 815 820 10.1161/01.ATV.0000158380.44231.fe 15692098
25. Diabetic vascular complications:pathophysiology, biochemical basis and potential therapeutic strategy. Yamagishi S, Imaizumi T, Curr Pharm 2005 11 2279 2299 10.2174/1381612054367300
26. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M, Nature 2000 404 787 790 10.1038/35008121 10783895
27. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Atherosclerosis 1998 138 271 280 10.1016/S0021-9150(98)00032-X 9690910
28. Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Kiener PA, Davis PM, Murray JL, Youssef S, Rankin BM, Kowala M, Int Immunopharmacol 2001 1 105 118 10.1016/S0162-3109(00)00272-1 11367508
29. Effects of statins on liver cell function and inflammation in septic rats. Stolf AM, Lívero Fdos R, Dreifuss AA, Bastos-Pereira AL, Fabosi IA, de Souza CE A, Gomes Lde O, Chicorski R, Brandt AP, Cadena SM, Telles JE, Hauser AB, Elferink RO, Zampronio AR, Acco A, J Surg Res 2012 178 888 897 10.1016/j.jss.2012.08.019 22954522
30. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Yamagishi S, Exp Gerontol 2011 46 217 224 10.1016/j.exger.2010.11.007 21111800
31. Diabetes control and complications trial, epidemiology of diabetes interventions and complications research group: intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S, Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group, N Engl J Med 2003 348 2294 2303 12788993
32. Novel inhibitors of advanced glycation endproducts. Rahbar S, Figarola JL, Arch Biochem Biophys 2003 419 63 79 10.1016/j.abb.2003.08.009 14568010
33. AGE and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I The AGE concept. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP, Cardiovasc Res 1998 37 586 600 10.1016/S0008-6363(97)00233-2 9659442
34. Suppression of the functionally coupled cyclooxygenase- 2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, Ucchino S, Spigonardo F, Bajocchi G, Bei R, Muraro R, Artese L, Piattelli A, Chiarelli F, Cuccurullo F, Mezzetti A, Circulation 2003 107 1479 1485 10.1161/01.CIR.0000056530.03783.81 12654603
35. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J, Circulation 2001 103 926 933 10.1161/01.CIR.103.7.926 11181465
36. Weight increase is associated with skeletal muscle immunostaining for advanced glycation end products, receptor for advanced glycation end products, and oxidation injury. de la Maza MP, Uribarri J, Olivares D, Hirsch S, Leiva L, Barrera G, Bunout D, Rejuvenation Res 2008 11 1041 1048 10.1089/rej.2008.0786 19086911